视频

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel

 

Authors Denis D, Beneton N, Laribi K, Maillard H

Received 19 August 2018

Accepted for publication 20 December 2018

Published 20 March 2019 Volume 2019:11 Pages 2241—2251

DOI https://doi.org/10.2147/CMAR.S138661

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Chien-Feng Li

Abstract: Mycosis fungoides (MF) is a low-grade cutaneous lymphoma accounting for more than half of primary cutaneous T-cell lymphomas (CTCLs). Due to the rarity of CTCL, randomized studies are lacking, and treatment is based mainly on the recent published European Organisation for Research and Treatment of Cancer guidelines. Basically, early-stage MF is treated with skin-directed treatments, whereas advanced-stage MF requires more aggressive therapies. Among the skin-directed therapies, nitrogen mustard has been used for more than 50 years. A gel formulation was developed recently, showing a slight decrease in efficacy, counterbalanced by better tolerance (essentially due to a decrease in delayed hypersensitivity reactions). This review aims to summarize the current management of MF and the role of chlormethine gel in the treatment of the disease.
Keywords: mycosis fungoides, nitrogen mustard, mechlorethamine, chlormethine, gel


 

摘要视频链接:Chlormethine gel on MF